Compare CALM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | NUVL |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 7.1B |
| IPO Year | 1996 | 2021 |
| Metric | CALM | NUVL |
|---|---|---|
| Price | $82.43 | $104.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $102.50 | ★ $135.00 |
| AVG Volume (30 Days) | ★ 973.8K | 598.4K |
| Earning Date | 01-07-2026 | 10-30-2025 |
| Dividend Yield | ★ 10.03% | N/A |
| EPS Growth | ★ 198.25 | N/A |
| EPS | ★ 26.04 | N/A |
| Revenue | ★ $4,398,616,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.20 | ★ N/A |
| Revenue Growth | ★ 65.80 | N/A |
| 52 Week Low | $79.55 | $55.54 |
| 52 Week High | $126.40 | $112.88 |
| Indicator | CALM | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 53.02 |
| Support Level | $86.62 | $100.42 |
| Resistance Level | $88.05 | $107.14 |
| Average True Range (ATR) | 2.16 | 3.09 |
| MACD | -0.06 | -0.66 |
| Stochastic Oscillator | 6.29 | 38.48 |
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.